Literature DB >> 15315707

Anaesthesia with midazolam/medetomidine/fentanyl in chinchillas (Chinchilla lanigera) compared to anaesthesia with xylazine/ketamine and medetomidine/ketamine.

J Henke1, C Baumgartner, I Röltgen, E Eberspächer, W Erhardt.   

Abstract

We studied four different drug regimes for anaesthetic management in chinchillas and evaluated and compared their cardiovascular and respiratory effects. In this randomized, cross-over experimental study, seven adult chinchillas, five females, two males [515 +/- 70 (SD) g] were randomly assigned to one of the following groups: group 1 [midazolam, medetomidine and fentanyl (MMF), flumazenil, atipamezole and naloxone (FAN); MMF-FAN] received 1.0 mg/kg midazolam, 0.05 mg/kg medetomidine and 0.02 mg/kg fentanyl i.m., and for reversal 0.1 mg/kg flumazenil, 0.5 mg/kg atipamezole and 0.05 mg/kg naloxone s.c. after 45 min; group 2 (MMF) 1.0 mg/kg midazolam, 0.05 mg/kg medetomidine and 0.02 mg/kg fentanyl i.m.; group 3 [xylazine/ketamine (X/K)] 2.0 mg/kg xylazine and 40.0 mg/kg ketamine i.m.; and group 4 [medetomidine/ketamine (M/K)] 0.06 mg/kg medetomidine and 5.0 mg/kg ketamine i.m. Reflexes were judged to determine anaesthetic stages and planes. Anaesthesia with X/K and M/K was associated with a prolonged surgical tolerance and recovery period. By reversing MMF, recovery period was significantly shortened (5 +/- 1.3 min versus 40 +/- 10.3 min in MMF without FAN, 73 +/- 15.0 min in X/K, and 31 +/- 8.5 min in M/K). Without reversal, MMF produced anaesthesia lasting 109 +/- 16.3 min. All combinations decreased respiratory and heart rate but compared with X/K and M/K, respiratory and cardiovascular complications were less in the MMF groups. Focussing on the clinical relevance of the tested combinations, completely reversible anaesthesia showed two major advantages: anaesthesia can be antagonized in case of emergency and routinely shortens recovery. In small animals particularly these advantages lead to less complications and discomfort and thus often can be lifesaving. As all analgesic components (medetomidine and fentanyl) are reversed, postoperative analgesia should be provided before reversal of anaesthesia. Copyright 2004 Blackwell Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315707     DOI: 10.1111/j.1439-0442.2004.00632.x

Source DB:  PubMed          Journal:  J Vet Med A Physiol Pathol Clin Med        ISSN: 0931-184X


  5 in total

1.  In Vivo Molecular Characterization of Abdominal Aortic Aneurysms Using Fibrin-Specific Magnetic Resonance Imaging.

Authors:  René M Botnar; Julia Brangsch; Carolin Reimann; Christian H P Janssen; Reza Razavi; Bernd Hamm; Marcus R Makowski
Journal:  J Am Heart Assoc       Date:  2018-05-30       Impact factor: 5.501

2.  Comparison of Dexmedetomidine-Ketamine with Isoflurane for Anesthesia of Chinchillas (Chinchilla lanigera).

Authors:  Lana Fox; Lindsey Bc Snyder; Christoph Mans
Journal:  J Am Assoc Lab Anim Sci       Date:  2016       Impact factor: 1.232

3.  Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl on physiological variables continuously measured by telemetry in Wistar rats.

Authors:  Maike Albrecht; Julia Henke; Sabine Tacke; Michael Markert; Brian Guth
Journal:  BMC Vet Res       Date:  2014-08-23       Impact factor: 2.741

4.  Effect of Doxycycline on Survival in Abdominal Aortic Aneurysms in a Mouse Model.

Authors:  Lisa C Adams; Julia Brangsch; Jan O Kaufmann; Dilyana B Mangarova; Jana Moeckel; Avan Kader; Rebecca Buchholz; Uwe Karst; Rene M Botnar; Bernd Hamm; Marcus R Makowski; Sarah Keller
Journal:  Contrast Media Mol Imaging       Date:  2021-04-27       Impact factor: 3.161

5.  Noninvasive imaging of vascular permeability to predict the risk of rupture in abdominal aortic aneurysms using an albumin-binding probe.

Authors:  Lisa C Adams; Julia Brangsch; Carolin Reimann; Jan O Kaufmann; Kristin Nowak; Rebecca Buchholz; Uwe Karst; Rene M Botnar; Bernd Hamm; Marcus R Makowski
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.